Quercetin, a Plant Polyphenol, Has Potential for the Prevention of Bone Destruction in Rheumatoid Arthritis

Kim, Hae-Rim; Kim, Bomi; Won, Ji-Yeon; Lee, Kyung-Ann; Ko, Hyun Sook; Kang, Young Sun; Lee, Sang‐Heon; Kim, Kyoung-Woon

doi:10.1089/jmf.2018.4259

Cited by 61 publications

(46 citation statements)

References 35 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Recent studies investigating the osteoclast-differentiation inhibitory effects of natural compounds, such as flavonoids or polyphenols, have been actively conducted ( Kim et al., 2018 ). However, prenylated xanthones have yet to be investigated for their role in inhibition of bone disease or osteoclast differentiation, despite their various antioxidant, anti-atherosclerotic, anti-inflammatory, and hepatoprotective activities ( Lee et al., 2009 ; Jeong et al., 2010 ; Kim et al., 2019 ).…”

Section: Discussionmentioning

confidence: 99%

Inhibitory Effect of Cudratrixanthone U on RANKL-Induced Osteoclast Differentiation and Function in Macrophages and BMM Cells

et al. 2020

View full text Add to dashboard Cite

Cudratrixanthone U (CTU) is a prenylated xanthone compound isolated from Maclura tricuspidata Bureau (Moraceae). Prenylated xanthones have been reported to exhibit a variety of biological activities. However, the effects of prenylated xanthone on osteoclast differentiation and function are still unclear. Excessive bone resorption by osteoclasts is considered a major cause of diseases such as osteoporosis. Accordingly, suppression of excessive osteoclast formation and function is one of strategies for treating osteoclast related bone diseases. In this study, CTU inhibited osteoclast differentiation and function in RAW264.7 macrophages and BMM cells induced by receptor activator of nuclear factor-κB ligand (RANKL). CTU regulated the formation of TRAF6-TAK1 complex in RANKL-induced RAW264.7 macrophages and BMM cells. Osteoclast-specific genes including those encoding matrix metallopeptidase 9 (MMP-9), dendritic cell-specific transmembrane proteins (DC-STAMP), cathepsin K (CTSK) and chemokine CC motif ligand 4 (CCL4) play an important role in bone resorption and migration, and were effectively regulated by CTU. These results suggest that CTU is a potential therapeutic agent in osteoporosis.

show abstract

Section: Discussionmentioning

confidence: 99%

Inhibitory Effect of Cudratrixanthone U on RANKL-Induced Osteoclast Differentiation and Function in Macrophages and BMM Cells

et al. 2020

View full text Add to dashboard Cite

show abstract

“…Moreover, this drug reduced swelling of the paw in model rats with arthritis; inhibited the proliferation and transfer of synovial cells and release of in ammatory cytokines; decreased the protein expression of in ammasome NLRP3, caspase-1, and IL-1β; inhibited in ammatory cell in ltration and angiogenesis; promoted apoptosis; reduced serum in ammatory factors IL-1β and TNF-α levels; and signi cantly inhibited the in ammatory reaction. Clinically, Herba tuberculate speranskia is used mostly for external application in rheumatic arthralgia, bone and muscle contracture, and pyogenic infections [13,[21][22][23][24][25]. In summary, the external application of this compound had antibacterial, anti-in ammatory, analgesic, and anticoagulatory effects against AGA.…”

Section: Discussionmentioning

confidence: 99%

Effects of external application of compound Qingbi granules on acute gouty arthritis with dampness-heat syndrome: A randomized control trial

Ren¹,

Meng²,

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background The use of anti-inflammatory and analgesic drugs such as nonsteroidal anti-inflammatory drugs(NSAIDs) for treating acute gout has limitations, such as a high incidence of adverse reactions in the gastrointestinal tract and toxicity in the liver, kidney, and heart. Hence, a new safe and effective treatment approach to reduce the use of anti-inflammatory and analgesic drugs, incidence of adverse reaction, and patients’ burden needs to be explored. This randomized controlled clinical trials investigated the clinical efficacy and safety of external application of compound Qingbi granules (CQBG) in treating acute gouty arthritis, providing evidence for designing a safe and effective optimization protocol of acute gouty arthritis (AGA) comprehensive treatment. Methods A total of 90 patients in line with the diagnostic standard of AGA were recruited and divided randomly into control, T1, and T2 groups (30 in each group). Participators in three groups all received Western–medicine–bastic treatment (low-purine diet, drinking water more than 2000 mL/d, oral loxoprofen, and NAHCO3). Besides, the T1 group received an external application of diclofenac diethylamine emulgel, while the T2 group received an external application of CQBG. Participators in control group were treated by single-use Western–medicine–bastic treatment. With a treatment course of 7 days and a follow-up for subsequent 7 days, the three groups were compared in terms of primary outcome indicators including swelling, pain improvement, and change in pain duration and secondary outcome indicators including serum C-reactive protein (CRP), uric acid (UA), and change in thickness of the inflammatory synovium of joints under ultrasound. Meanwhile, the safety of the protocol was evaluated. Results The three groups of patients had no obvious differences in age, body mass index, history of gout, complication, and so on before recruitment. A comparison between pretreatment and post-treatment revealed remarkable reductions in the arthralgia VAS score and the swelling score in the three groups after the treatment and the improvements in the T2 group were more obvious than those in the T1 and control groups (P < 0.05). Regarding onset-time of pain improvement and pain duration, the T2 group had more significant efficacy compared with the other two groups (P < 0.05). The serum CRP and blood UA levels in the three groups significantly decreased after the treatment, but with no significant inter-group difference. The improvement in thickness of the inflammatory synovium in joints tested by ultrasound was more significant in the T2 group than in the control group (P < 0.05). For safety evaluations, no significant difference in the incidence of adverse events was found. Conclusions The external application of CQBG combined with Western–medicine–bastic treatment in patients with AGA improved arthralgia and swelling, shortened the period of taking NSAIDs, and reduced the levels of CRP and serum UA. Its therapeutic effect was significantly better than the effect of single-use Western medicine bastic treatment and additive diclofenac diethylamine emulgel. The study provided evidence for the clinical application of CQBG combined with Western medicine in treating AGA. Trial registration: ChiCTR, ChiCTR1800018020. Registered 27 August 2018, http://www.chictr.org.cn/showproj.aspx?proj=27138

show abstract

“…Moreover, this drug reduced the swelling of the paw in model rats with arthritis; inhibited the proliferation and transfer of synovial cells and release of in ammatory cytokines; decreased the protein expression of in ammasome NLRP3, caspase-1, and IL-1b; inhibited in ammatory cell in ltration and angiogenesis; promoted apoptosis; reduced serum in ammatory factors IL-1β and TNF-α levels; and signi cantly inhibited the in ammatory reaction. Clinically, Herba tuberculate speranskia is used mostly for external application in rheumatic arthralgia, bone and muscle contracture, and pyogenic infections [20,[31][32][33][34][35]. In summary, the external application of this compound had antibacterial, anti-in ammatory, analgesic, and anticoagulatory effects against AGA.…”

Section: Discussionmentioning

confidence: 99%

Effects of external application of compound Qingbi granules on acute gouty arthritis with dampness-heat syndrome: A randomized controlled trial

Ren

Meng²,

Liu

et al. 2020

Preprint

View full text Add to dashboard Cite

Background and aim: The use of anti-inflammatory and analgesic drugs such as nonsteroidal anti-inflammatory drugs(NSAIDs) for treating acute gout has limitations, such as adverse reactions in the gastrointestinal tract and toxicity in the liver, kidney, and heart. Hence, a new safe and effective treatment approach needs to be explored to reduce the use of anti-inflammatory and analgesic drugs, incidence of adverse reactions, and patients’ burden. This randomized controlled clinical trial aimed to investigate the clinical efficacy and safety of the external application of compound Qingbi granules (CQBG) in treating acute gouty arthritis(AGA), providing evidence for designing a safe, effective, and optimized protocol for AGA comprehensive treatment.Methods: A total of 90 patients in line with the diagnostic standard of AGA were recruited and randomly divided into control, T1, and T2 groups (30 in each group). All the participators in the three groups all received Western–medicine–bastic treatment (low-purine diet, drinking water more than 2000 mL/d, oral loxoprofen, and NAHCO3). Besides, the T1 group received an external application of diclofenac diethylamine emulgel, while the T2 group received an external application of CQBG. The participants in the control group received single-use Western–medicine–bastic treatment. With a treatment course of 7 days and a follow-up of 7 days, the three groups were compared in terms of primary outcome indicators, including swelling, pain improvement, and change in pain duration and secondary outcome indicators, including serum C-reactive protein (CRP) level, uric acid (UA) level, and change in the thickness of the inflammatory synovium of joints under ultrasound. Meanwhile, the safety of the protocol was evaluated.Results: The three groups of patients had no apparent differences in age, body mass index, history of gout, complications, and so on before recruitment. A comparison between pretreatment and post-treatment revealed remarkable reductions in the arthralgia visual analog scale score(VAS) and the swelling score in the three groups after the treatment and the improvements in the T2 group were more significant than those in the T1 and control groups (P < 0.05). Regarding the onset time of pain improvement and pain duration, the T2 group had more significant efficacy compared with the other two groups (P < 0.05). The serum CRP and blood UA levels in the three groups significantly decreased after the treatment, but with no significant intergroup difference. The improvement in the thickness of the inflammatory synovium in joints tested by ultrasound was more significant in the T2 group than in the control group (P < 0.05). For safety evaluations, no significant difference in the incidence of adverse events was found.Conclusions: The external application of CQBG combined with Western–medicine–basic treatment in patients with AGA improved arthralgia and swelling, shortened the period of taking NSAIDs, and reduced the levels of CRP and serum UA. Its therapeutic effect was significantly better than the effect of single-use Western-medicine-basic treatment. The study provided evidence for the clinical application of CQBG combined with Western medicine in treating AGA.Trial registration: ChiCTR, ChiCTR1800018020. Registered 27 August 2018, http://www.chictr.org.cn/showproj.aspx?proj=27138

show abstract

Quercetin, a Plant Polyphenol, Has Potential for the Prevention of Bone Destruction in Rheumatoid Arthritis

Cited by 61 publications

References 35 publications

Inhibitory Effect of Cudratrixanthone U on RANKL-Induced Osteoclast Differentiation and Function in Macrophages and BMM Cells

Inhibitory Effect of Cudratrixanthone U on RANKL-Induced Osteoclast Differentiation and Function in Macrophages and BMM Cells

Effects of external application of compound Qingbi granules on acute gouty arthritis with dampness-heat syndrome: A randomized control trial

Effects of external application of compound Qingbi granules on acute gouty arthritis with dampness-heat syndrome: A randomized controlled trial

Contact Info

Product

Resources

About